Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18229654 | 1.00 | MEN1 (0.33) | MEN1KMT2AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL18229702 | 0.91 | LMNA (0.33) | MEN1KMT2AHTTALDH1A1LMNA | |
| SCHEMBL18229734 | 0.91 | LMNA (0.33) | MEN1KMT2AHTTALDH1A1LMNA | |
| SCHEMBL19810006 | 0.87 | MEN1 (0.39) | MEN1KMT2AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL19810007 | 0.87 | MEN1 (0.39) | MEN1KMT2AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL18229666 | 0.83 | ALDH1A1 (0.36) | MEN1KMT2AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL18229667 | 0.83 | ALDH1A1 (0.36) | MEN1KMT2AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL20156625 | 0.82 | SLC13A5 (0.32) | MEN1KMT2AHTTALDH1A1LMNA | |
| SCHEMBL19829243 | 0.77 | MEN1 (0.37) | MEN1KMT2AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL19809983 | 0.73 | LMNA (0.41) | MEN1KMT2AALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597401-B2 | Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180134724-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OMACETAXINE AND CEPHALOTAXINE DERIVATIVES THEREOF | CURIA BUFFALO R&D, LLC | 2018-05-17 | — | — | US | disclosed |
| WO-2016182850-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OMACETAXINE AND CEPHALOTAXINE DERIVATIVES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597401-B2 | Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof | MAOB, MAOA, NISCH | MEN1 2593/4885KMT2A 2419/4885HTT 944/4885 |
| US-20180134724-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OMACETAXINE AND CEPHALOTAXINE DERIVATIVES THEREOF | MAOB, MAOA, NISCH | MEN1 2593/4885KMT2A 2419/4885HTT 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.